Middle East & Africa Biosurgery Market Outlook, 2031

Market Drivers

• Healthcare transformation and infrastructure investment across the region: The Middle East and Africa are experiencing unprecedented healthcare infrastructure development, driven by government initiatives and economic diversification strategies. Saudi Arabia's Vision 2030 has allocated substantial resources to healthcare, with total health expenditure exceeding SAR 175 billion annually. The Kingdom's Ada'a Health initiative has become one of the leading transformation programs, with healthcare providers conducting more than 11,300 surgeries in a single week. In the UAE, AED 5.745 billion was allocated to healthcare and community prevention services in 2025. South Africa's health spending reached 9.14% of GDP in 2025 the highest on record. These investments provide the financial and institutional foundation for sustained surgical activity and biosurgical product utilization across the region.
• Rising surgical volumes and expanding healthcare access: The Middle East and Africa are witnessing significant growth in surgical volumes across both public and private healthcare sectors. Surgical procedure volumes in the region are forecast to more than double by 2031, led by robotic-assisted growth in urology and gynecology, rising bariatric demand, and continued investments in healthcare infrastructure. Saudi Arabia accounts for approximately 950,000 major surgical procedures annually across the GCC, representing roughly 50% of the GCC market. In the UAE, Burjeel Holdings performed 22,930 surgeries in Q2 2025, marking an 18.7% year-on-year increase. In South Africa, Gauteng hospitals performed 806 life-changing surgical procedures in 12 hours across 29 hospitals as part of the Nelson Mandela Day Surgical Marathon.
• Demographic pressures from growing and aging populations: The Middle East and Africa face significant demographic pressures driving demand for surgical interventions. The GCC countries have rapidly growing populations with increasing life expectancy Saudi Arabia's life expectancy has reached 78.7 years, while the UAE achieves life expectancy of 82.9 years. The rising prevalence of chronic diseases, including diabetes, cardiovascular disorders, and obesity, is leading to more surgical interventions across all age groups. In the UAE, diabetes affects a significant portion of the population, while Saudi Arabia has launched nationwide campaigns to strengthen compliance with bariatric surgery regulations. South Africa's aging population, with 7.1% aged 65 and older, continues to drive demand for surgical interventions.

Market Challenges

• Healthcare spending constraints and infrastructure gaps across Africa: Despite significant investment in some countries, much of Africa faces persistent healthcare financing challenges. Sub-Saharan African governments spend on average only 2% of GDP on health less than half the aspirational target of 5%. More than 48 countries remain way below the Abuja Declaration targets as of 2025. Per capita health expenditure in Africa remains among the lowest globally, with African Health Ministers having only $40 per capita for health expenditure compared to $4,000 in many high-income countries. These financial constraints create significant pricing pressure on biosurgical products and may limit adoption of premium-priced advanced biologics in public healthcare sectors.
• Regulatory fragmentation and varying compliance standards: The Middle East and Africa regulatory landscape presents challenges for biosurgery manufacturers. In Saudi Arabia, the Saudi Food and Drug Authority (SFDA) has evaluated 295 clinical studies for medical devices. In the UAE, the "Medical Devices Regulation, Cabinet Resolution No. 32 of 2023" mandates the use of biocompatible materials in surgical procedures. In South Africa, the South African Health Products Regulatory Authority (SAHPRA) regulates medical devices under the Medicines and Related Substances Act, with Quality Management System requirements taking effect from June 1, 2025. Navigating these varying requirements increases time-to-market and compliance costs.
• Economic volatility and currency fluctuations: Middle Eastern and African economies face economic challenges that affect the biosurgery market. Currency fluctuations impact the cost of imported medical devices and biosurgical products, which are predominantly imported across the region. South Africa's health spending per capita stands at only $573 in 2025, reflecting significant economic constraints. The region's reliance on imported medical technologies creates vulnerability to currency fluctuations and trade disruptions.

Market Trends

• Accelerating adoption of robotic-assisted and minimally invasive surgery: The Middle East and Africa are witnessing rapid adoption of robotic-assisted surgical techniques, particularly in the Gulf countries. Saudi Arabia has introduced robotic surgery at King Abdullah Medical City in Makkah, supporting procedures in thoracic surgery, urology, and oncology. The Kingdom's first pancreatic tumor removal using robotic technology was performed in October 2025. King Faisal Specialist Hospital performed the world's first fully robotic heart and liver lobe transplants. In the UAE, MoHAP has launched robotic surgeries programs in obstetrics and gynecology. The Middle East minimally invasive surgery market is expected to grow from USD 7.37–7.80 billion in 2025 to USD 13.41 billion by 2033 at a CAGR of 7.02%. This shift creates new opportunities for biosurgical products specifically designed for robotic and minimally invasive applications.
• Regulatory modernization and harmonization: Regulatory authorities across the region are modernizing frameworks to facilitate faster market access for innovative medical devices. The UAE's Emirates Drug Establishment (EDE), established in January 2025, now serves as the sole federal authority for medical devices. The SFDA in Saudi Arabia continues to update its regulatory framework, publishing MDS-G27 on digital health products. COFEPRIS in Mexico and other regional regulators are implementing abbreviated pathways to accelerate approvals. These regulatory reforms support continued innovation and market entry for advanced biosurgical products.
• Growing medical tourism and private healthcare investment: The Middle East, particularly the UAE and Saudi Arabia, is positioning itself as a premier destination for medical tourism. Dubai welcomed over 691,000 international health tourists in 2023. The UAE ranks first globally in 10 healthcare competitiveness indicators in the IMD World Competitiveness Yearbook 2026. Burjeel Holdings reported revenue of AED 25.8 billion for fiscal year 2024. These investments in private healthcare infrastructure support the adoption of advanced biosurgical products and premium-priced technologies.